India-based drug maker Lupin Ltd announced on December 1 that it has received approval from the FDA for its pegfilgrastim biosimilar Armlupeg (pegfilgrastim-unne). Armlupeg’s indications include: (1) to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile … Continue reading Lupin Scores Its First FDA-Approved Biosimilar